A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapy The BBoPCO study (Botensilimab and Balstilimab Optimization in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results